Cocrystal Pharma, Inc. financial data

Symbol
COCP on Nasdaq
Industry
Pharmaceutical Preparations
Location
19805 N. Creek Parkway, Bothell, WA
State of incorporation
DE
Fiscal year end
December 31
Former names
BIOZONE PHARMACEUTICALS, INC. (to 3/25/2014), International Surf Resorts, Inc. (to 3/4/2011)
Latest financial report
10-K - Q4 2024 - Mar 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 744 % -45.1%
Debt-to-equity 25.1 % +174%
Return On Equity -113 % -97.8%
Return On Assets -90 % -72.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 10.2M shares 0%
Common Stock, Shares, Outstanding 10.2M shares 0%
Entity Public Float 18M USD -2.7%
Common Stock, Value, Issued 10K USD 0%
Weighted Average Number of Shares Outstanding, Basic 10.2M shares +5.42%
Weighted Average Number of Shares Outstanding, Diluted 10.2M shares +5.42%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 12.5M USD -17.4%
General and Administrative Expense 5.34M USD -10.8%
Operating Income (Loss) -17.9M USD +3.67%
Nonoperating Income (Expense) 374K USD -35%
Net Income (Loss) Attributable to Parent -17.5M USD +2.67%
Earnings Per Share, Basic -1.72 USD/shares +8.02%
Earnings Per Share, Diluted -1.72 USD/shares +8.02%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 9.86M USD -62.6%
Assets, Current 11.6M USD -60.2%
Property, Plant and Equipment, Net 153K USD -43.5%
Operating Lease, Right-of-Use Asset 1.69M USD -8.48%
Assets 13.5M USD -57%
Accounts Payable, Current 1.54M USD +26.2%
Employee-related Liabilities, Current 117K USD +7.34%
Liabilities, Current 2.43M USD -25.6%
Operating Lease, Liability, Noncurrent 1.51M USD -6.7%
Liabilities 3.93M USD -19.3%
Retained Earnings (Accumulated Deficit) -333M USD -5.54%
Stockholders' Equity Attributable to Parent 9.52M USD -63.9%
Liabilities and Equity 13.5M USD -57%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.5M USD -44.7%
Net Cash Provided by (Used in) Financing Activities -7K USD -16.7%
Net Cash Provided by (Used in) Investing Activities -8K USD +82.2%
Common Stock, Shares Authorized 100M shares -33.3%
Common Stock, Shares, Issued 10.2M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -4.51M USD -42.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 13.1M USD
Deferred Tax Assets, Valuation Allowance 35.2M USD +11.9%
Deferred Tax Assets, Gross 35.6M USD +11.5%
Operating Lease, Liability 1.81M USD -2.54%
Depreciation 45K USD
Payments to Acquire Property, Plant, and Equipment 8K USD -82.2%
Lessee, Operating Lease, Liability, to be Paid 2.13M USD -3.92%
Property, Plant and Equipment, Gross 2.08M USD +0.39%
Operating Lease, Liability, Current 301K USD +25.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 419K USD +21.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 407K USD +54.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 324K USD -11%
Lessee, Operating Lease, Liability, to be Paid, Year Three 415K USD +16.9%
Deferred Tax Assets, Operating Loss Carryforwards 23.7M USD +7.58%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares
Lessee, Operating Lease, Liability, to be Paid, Year Four 376K USD +3.01%
Operating Lease, Payments 56K USD +12%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 35.2M USD +11.9%
Share-based Payment Arrangement, Expense 643K USD -19.7%
Interest Expense -220K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares